Solanezumab

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Cognitive ImpairmentMemoryDementia

279 competitors in Cognitive Impairment

#DrugCompanyPhaseTrials

1

Actos

Takeda

Phase 3

32

Farxiga

AstraZeneca

Phase 3

13

Aquasol E

NNational Eye Institute (NEI)

Phase 3

14

Provigil

NNuvo Research GmbH

Phase 3

15

Xarelto

WWim Janssens

Phase 3

16

Viagra

VViatris Specialty LLC

Phase 3

17

Donepezil Hydrochloride

Eisai

Phase 3

38

Statins

Sanofi

Phase 3

19

Galantamine Hydrobromide

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

410

Karxt

Bristol-Myers Squibb

Phase 3

—Show 38 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Alzheimer's Disease3 trials

Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease

Terminated·Eli Lilly·Phase 3·NCT01127633·1,457 enrolled

Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease

Completed·Eli Lilly·Phase 2·NCT00749216·33 enrolled

Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo

Terminated·Eli Lilly·Phase 3·NCT01900665·2,129 enrolled

Dementia2 trials

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.

Completed·WWashington University School of Medicine·Phase 2/3·NCT04623242·194 enrolled

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

Active, not recruiting·WWashington University School of Medicine·Phase 2/3·NCT01760005·490 enrolled

Memory1 trial

Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss

Completed·Eli Lilly·Phase 3·NCT02008357·1,169 enrolled

Prodromal Alzheimer's Disease1 trial

A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease

Terminated·Eli Lilly·Phase 3·NCT02760602·26 enrolled

Cognitive impairment1 trial

A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)

Terminated·Eli Lilly·Phase 1·NCT02614131·50 enrolled

1 more indication

Biomarker1 trial

A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's

Completed·Eli Lilly·Phase 2·NCT01148498·55 enrolled

Details

Drug Info

Related News